Rezolute Appoints Sunil Karnawat as Chief Commercial Officer.

Rezolute has appointed Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. Karnawat has a proven track record of successfully launching therapies for ultra-rare diseases. He will lead the commercialization efforts for Rezolute's Phase 3 studies for congenital and tumor hyperinsulinism. Karnawat's appointment is seen as pivotal in advancing the company's therapy, ersodetug, toward commercialization.

Rezolute, Inc. (RZLT) has appointed Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. Dr. Karnawat, with over 25 years of experience in biopharmaceuticals and medical devices, will lead the company’s commercial strategy as it advances its antibody therapy, ersodetug, through Phase 3 studies for congenital and tumor hyperinsulinism.

Karnawat has a proven track record of successfully launching therapies for ultra-rare diseases, including four such launches at Ultragenyx. His appointment is seen as pivotal in advancing Rezolute's therapy toward commercialization. The company aims to build a world-class commercial organization to deliver ersodetug to patients with high unmet needs.

Rezolute's stock has been rated as a "Buy" with a $12.00 price target by analysts [1]. Despite challenging financial performance and persistent losses, the stock shows moderate upward momentum and positive corporate events, including significant funding and promising clinical trial progress, offer potential upside.

Sunil Karnawat's appointment is part of Rezolute's efforts to advance ersodetug through Phase 3 studies and build a commercial organization to deliver the therapy to patients. His experience and expertise in commercializing biopharmaceuticals and medical devices are expected to be instrumental in this process.

References:
[1] https://www.tipranks.com/news/company-announcements/rezolute-appoints-new-chief-commercial-officer
[2] https://www.globenewswire.com/news-release/2025/08/20/3136321/0/en/Rezolute-Appoints-Seasoned-Commercial-Executive-Sunil-Karnawat-as-Chief-Commercial-Officer.html